BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-abbv-apogee-immunology-merger-q3-2026-close-window@catalyst-calendar.local
DTSTAMP:20260720T200622Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:AbbVie收购Apogee的109亿美元免疫炎症管线并购Q3交割窗口
DESCRIPTION:AbbVie与Apogee于2026-06-22宣布达成最终协议，AbbVie拟以每股135.11美元现金收购Apogee，交易股权价值约109亿美元，预计2026年三季度完成，需Apogee股东批准和监管审批。该交易可能重定价免疫炎症临床管线资产和大型药企并购偏好。\\nImpact score: 78\\nExpected: 关注Apogee股东投票、监管审批、交易完成时间及市场对IL-13/TSLP等免疫炎症资产峰值销售和并购估值的再定价。\\nAffected: APGE(target\, positive\, score 92)\; ABBV(acquirer\, mixed\, score 76)\; XBI(etf\, mixed\, score 70)\; IBB(etf\, mixed\, score 66)\; REGN(peer\, mixed\, score 58)\; LLY(peer\, mixed\, score 54)\\nSources: SEC filed joint press release: https://www.sec.gov/Archives/edgar/data/1974640/000114036126025844/ef20076505_ex99-1.htm\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-abbv-apogee-immunology-merger-q3-2026-close-window
CATEGORIES:mna\,US\,M&A\,immunology\,inflammation\,large pharma\,biotech
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: AbbVie收购Apogee的109亿美元免疫炎症管线并购Q3交割窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: AbbVie收购Apogee的109亿美元免疫炎症管线并购Q3交割窗口
END:VALARM
END:VEVENT
END:VCALENDAR